Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study

What this Trial Is About

Researchers are investigating different types of heart failure and cardiomyopathies, including amyloidosis, in adults aged 18 and older. This observational study aims to better understand how these heart conditions develop and progress over time by examining clinical features alongside proteomic, metabolomic, genomic, and imaging data. The goal is to improve precision medicine by matching the right treatments to the right patients to maximize benefits and reduce side effects. Participants include those with and without heart failure, categorized into groups based on their left ventricular ejection fraction: normal (50% or higher) and reduced (less than 50%). The study collects baseline and one-year follow-up blood samples, including DNA. Clinical data such as heart failure history, causes, other medical conditions, lab results, echocardiograms, images, and treatment details are also gathered. During the study, researchers track major adverse cardiovascular events including death and hospitalizations related to heart failure and cardiovascular issues, as well as kidney injury. These outcomes are monitored over time up to 60 months after study closure. Participants undergo assessments at enrollment and after one year, providing valuable information to enhance understanding of heart failure subtypes and treatment effects.

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure